Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease

Inclusion Criteria:

* Patient has one lesion that is treatable with SBRT.
* Patient has at least 1 site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) or Magnetic resonance imaging (MRI) which will not be irradiated.
* Histological confirmation of malignancy (primary or metastatic tumor).
* Patient may have any prior therapy allowed aside from having had prior radiotherapy to the treatment site.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
* Patient's screening laboratory values must meet protocol limits.
* Patient must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patient has had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
* Patient receiving any investigational or experimental agents other than immunotherapy.
* Patient who has had any prior radiotherapy to the treatment site(s).
* Patient is a pregnant woman (pregnant women are excluded from this study because radiation treatment has known potential for teratogenic or abortifacient effects).
* Patient refuses to sign informed consent.